1. Articles in category: Other Business News

    1-24 of 1170 1 2 3 4 ... 47 48 49 »
    1. Perimeter Medical Imaging Closes Oversubscribed $C4.4M Financing

      Perimeter Medical Imaging Closes Oversubscribed $C4.4M Financing

      Perimeter Medical Imaging, Inc., the leader in real-time tissue imaging in the operating suite is pleased to announce the completion of a pre-public financing round raising $C4.4million. Perimeter intends to go public via a reverse takeover (RTO) with New World Resources (NW) in Q4 of this year. Funds raised in this pre-public round and anticipated RTO will support the commercialization of Perimeter's U.S. Food and Drug Administration (FDA) cleared OTISTM medical imaging technology. OTISTM is deployed in the surgical suite, empowering surgeons with real-time tissue imaging to help optimize cancer surgery outcomes. "We are pleased to have ...

      Read Full Article
    2. Avinger Announces Presentations by Key Opinion Leaders at AMP 2019 Clinical Conference

      Avinger Announces Presentations by Key Opinion Leaders at AMP 2019 Clinical Conference

      Avinger, Inc. (NASDAQ: AVGR ), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced four podium presentations featuring the Company’s Lumivascular technology at the annual AMP (Amputation Prevention Symposium) conference occurring last week. Key opinion leaders in the fields of interventional cardiology highlighted Avinger ’s Lumivascular technology, which includes the Pantheris family of image-guided atherectomy products and the Ocelot family of image-guided chronic total occlusion (CTO) crossing products, in the following sessions: Dr. Thomas Davis, an interventional cardiologist at Eastlake Cardiovascular and one ...

      Read Full Article
      Mentions: Avinger
    3. Dr. Kester Nahen joins Notal Vision as Chief Commercial Officer

      Dr. Kester Nahen joins Notal Vision as Chief Commercial Officer

      Notal Vision, Inc., a company focused on advancing eye care with precision medicine by extending disease management from the clinic to the home, is pleased to announce the appointment of Kester Nahen, PhD to Chief Commercial Officer. Dr. Nahen is a medical device industry expert and brings more than 18 years of well-rounded international business experience in product management, medical science, clinical research, marketing, sales, professional education, and business development to the company. "I am delighted to welcome Kester to the Notal Vision executive team,” stated Dr. Susan Orr, Chief Executive Officer of Notal Vision. “I am confident that his ...

      Read Full Article
    4. NinePoint Medical Announces FDA Clearance for Pancreatic and Biliary Applications of the NvisionVLE® Imaging System

      NinePoint Medical Announces FDA Clearance for Pancreatic and Biliary Applications of the NvisionVLE® Imaging System

      NinePoint Medical, Inc ., a transformative medical device company pioneering the use of a real-time optical imaging platform for gastrointestinal applications, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market the NvisionVLE® Imaging System for use in the pancreas and bile duct. These anatomical indications add to the previously existing esophageal applications for NinePoint’s state-of-the-art Optical Coherence Tomography (OCT) imaging platform. The NvisionVLE Imaging System provides physicians real-time, high-resolution volumetric images of the tissue surface and subsurface. This allows gastroenterologists to thoroughly evaluate tissue for regions of interest that may not be visible ...

      Read Full Article
    5. Altris AI algorithm for retinal conditions detection on Optical Coherence Tomography (OCT) scans gets European CE-mark certification

      Altris AI algorithm for retinal conditions detection on Optical Coherence Tomography (OCT) scans gets European CE-mark certification

      Altris AI (Altris, Inc), a global artificial intelligence (AI) healthcare company, announced that it has received the CE Mark approval for its Standard Functionality for retinal conditions detection on Optical Coherence Tomography (OCT) scans. Altris AI Standard Functionality is ready for preliminary screening of retinal diseases in clinical practice. Altris AI detects retinal pathological signs of more than 30 retinal diseases and classifies them according to severities. Altris AI Standard Functionality for OCT scans interpretation, the first of multiple Altris AI versions, is now approved for commercial sale within the European Union. Altris AI diagnostic software is based on computer ...

      Read Full Article
      Mentions: Altris AI Huvitz
    6. Avinger Announces Pantheris SV Limited Launch and Successful Treatment of First Patients in the United States

      Avinger Announces Pantheris SV Limited Launch and Successful Treatment of First Patients in the United States

      Avinger, Inc. ( Nasdaq: AVGR ), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that physicians in four U.S. sites have successfully treated several patients with the Pantheris SV (Small Vessel) image-guided atherectomy system. These initial cases are part of a limited launch at up to 13 leading clinical centers prior to expanding commercial distribution to additional treatment facilities in the U.S. Pantheris SV, a product line extension of Avinger’s onboard image-guided atherectomy platform, expands Avinger’s portfolio of atherectomy devices for ...

      Read Full Article
      Mentions: Avinger
    7. China's diagnostic technology gets U.S. FDA approval

      China's diagnostic technology gets U.S. FDA approval

      A new diagnostic technology developed by Chinese scientists for improving coronary heart disease treatment has received market approval from the U.S. Food and Drug Administration (FDA), according to China's Ministry of Science and Technology Monday. The technology, called Quantitative Flow Ratio (QFR) measurement system, was jointly developed by Pulse Medical Imaging Technology (Shanghai) Co and a group of researchers with Shanghai Jiaotong University. Based on the computational analysis of X-ray coronary angiography, the system is able to obtain QFR noninvasively, which can evaluate coronary artery blockage and function and then help doctors decide whether a patient needs to ...

      Read Full Article
    8. Notal Vision Diagnostic Clinic reports completion of 6 million ForeseeHome AMD home-monitoring tests

      Notal Vision Diagnostic Clinic reports completion of 6 million ForeseeHome AMD home-monitoring tests

      Notal Vision, Inc., a company focused on advancing eye care with precision medicine by extending disease management from the clinic to the home, celebrates the completion of six million patient tests performed with ForeseeHome, the first FDA-cleared home-monitoring device for patients with intermediate dry Age-related Macular Degeneration (AMD) at risk for developing wet AMD. ForeseeHome uses a patented technology, Preferential Hyperacuity Perimetry® (PHP), that can identify minute changes in the central 14 degrees of visual field before the patient has any visual symptoms. During the test, which takes about three minutes, the central macula is evaluated for changes in metamorphopsia ...

      Read Full Article
      Mentions: Notal Vision
    9. ZEISS Marks Milestone for its New North America High Tech Site in Dublin, California

      ZEISS Marks Milestone for its New North America High Tech Site in Dublin, California

      The internationally leading optics and optoelectronics technology enterprise ZEISS completed the “steel topping out” phase of its new high tech site in the San Francisco Bay Area. The new site in Dublin is an integral part of ZEISS’ global investment strategy and is one element in a string of international projects aimed at expanding, modernizing and realigning sites that ZEISS has been implementing in locations such as Germany, Europe and Asia since 2011. “Our investments are focused on leveraging the existing potential in our growth markets,” explains Dr. Christian Mueller, Member of the Executive Board and CFO of the ZEISS ...

      Read Full Article
    10. Lumedica Receives NIH Grant for Low Cost Retinal Optical Coherence Tomography for Point of Care Use

      Lumedica Receives NIH Grant for Low Cost Retinal Optical Coherence Tomography for Point of Care Use

      Lumedica Receives a 2019 NIH Grant for $499,978 for Low Cost Retinal Optical Coherence Tomography for Point of Care Use. The principal investigator is William Brown. The program began in 2016 and ends in 2021. Below is a summary of the proposed work. The objective of this research is to create a clinical prototype of a new optical coherence tomography (OCT) system suitable for diagnostic retinal imaging at the point of care. The target system price will be one third the price of currently available research OCT systems while providing performance comparable to other entry level OCT imaging systems ...

      Read Full Article
    11. ZEISS Ophthalmic Digital Summit 2019

      ZEISS Ophthalmic Digital Summit 2019

      In partnership with ODwire, Carl Zeiss Meditec, Inc. and Carl Zeiss Vision invite you to the ZEISS Ophthalmic Digital Summit 2019 . This two-day complimentary program offers live sessions and an interactive product showcase—all within a virtual exhibit hall—designed to provide you with the latest technology innovations and clinical solutions for your practice. Taught by industry leaders , you'll get trained and informed on how the Integrated Diagnostic Imaging platform and ZEISS leading imaging technologies will help shape the future of your practice. Event attendees will also be eligible for special show promotions and discounts on ZEISS instruments.

      Read Full Article
    12. Avinger Enrolls First 50 Patients in INSIGHT Clinical Trial

      Avinger Enrolls First 50 Patients in INSIGHT Clinical Trial

      Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the 50 th patient enrolled in its INSIGHT clinical trial. The INSIGHT trial is a prospective, global, single arm, multi-center study to evaluate the safety and effectiveness of the Pantheris ® Lumivascular atherectomy system for treating in-stent restenosis (ISR) in lower extremity arteries. Dr. Jaafer Golzar, Avinger’s Chief Medical Officer and a highly experienced interventionalist, noted, “We are pleased to have the first 50 cases completed as part of our INSIGHT IDE study. Early ...

      Read Full Article
      Mentions: Avinger
    13. Avinger Announces Commercial Launch of Ocelot in Australia

      Avinger Announces Commercial Launch of Ocelot in Australia

      First Patients Treated Successfully in Australia with Image-Guided CTO-Crossing Device REDWOOD, CA / ACCESSWIRE / July 8, 2019 / Avinger, Inc. (NASDAQ: AVGR ), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the commercial launch of its Ocelot image-guided chronic total occlusion (CTO) crossing system in Australia. As part of the Company’s exclusive distribution agreement with Diverse Devices Pty Ltd. for Avinger’s proprietary Lumivascular products in Australia, Ocelot completed the registration process with the Therapeutic Goods Administration (TGA) and is included on the Australian Register of Therapeutic ...

      Read Full Article
      Mentions: Avinger
    14. Lumedica Receives $1M Phase II NIH-SBIR Grant, in Support of Detecting Eye Disease Around the World

      Lumedica Receives $1M Phase II NIH-SBIR Grant, in Support of Detecting Eye Disease Around the World

      Lumedica Inc., a privately held company, focused on improving access to eye care by creating low-cost, high performance, Optical Coherence Tomography (OCT) systems for research and clinical applications, received a $1M Phase II NIH-NEI SBIR grant in order to continue system and product development. OCT is considered the gold standard for early detection of Macular Degeneration, Diabetic Retinopathy and Glaucoma, all of which can occur without symptoms. When these diseases are detected early — such as with OCT — they can be managed without patients losing their vision. “We are grateful for the ongoing support from the NIH-NEI, said Principal Investigator and ...

      Read Full Article
      Mentions: Lumedica
    15. PhotoniCare Looks Behind Ear Drums to Help Diagnose Ear Infections

      PhotoniCare Looks Behind Ear Drums to Help Diagnose Ear Infections

      Middle ear infections are one of the most common reasons for visits to the pediatrician. However, because the middle ear is hidden from view by the ear drum, physicians must diagnose based on symptoms and a limited physical exam — and when patients have ambiguous or borderline symptoms, accurate diagnosis can be challenging. PhotoniCare’s TOMi Scope uses near-infrared light waves to provide 3D views beyond the ear drum into the middle ear, allowing physicians to visualize and better diagnose middle ear infections. Co-founder and CEO Ryan Shelton, Ph.D. answered a few of our questions about his company’s beginnings ...

      Read Full Article
    16. Mentice and Siemens Healthineers bring a virtual patient to the angio-suite

      Mentice and Siemens Healthineers bring a virtual patient to the angio-suite

      Siemens Healthineers, a leading medical technology company and Mentice AB, a world leader in simulation solutions for endovascular therapies, announced today the collaboration to fully integrate Mentice’s VIST® Virtual Patient into the Artis icono angiography system from Siemens Healthineers. The VIST® Virtual Patient thus becomes a fully integrated simulation solution for the angio-suite. The global partnership between the two companies will allow interventional radiologists, neuroradiologists, and cardiologists to perform vascular and cardiac interventions on a virtual patient inside the angio-suite. “With an ever-increasing complexity of new interventional procedures, our customers strive to acquire and retain procedural skills while optimizing ...

      Read Full Article
      Mentions: Siemens
    17. New Hope for Port Wine Stain Patients from A Novel Image-Guided Treatment

      New Hope for Port Wine Stain Patients from A Novel Image-Guided Treatment

      Michelson Diagnostics Ltd. (MDL) announces increased outcome benefits from a powerful new treatment approach for patients with Port Wine Stain birthmarks and other disfiguring conditions of the superficial blood vessels in skin, such as hemangiomas, rosacea and spider veins. The novel technique, known as OCT image-guided treatment, utilizes a high-resolution laser scanner to detect and image the tiny blood vessels in the skin, so that the depth, diameter and density of these vessels can be accurately characterized. This information is crucial for optimizing the settings for laser or Broadband Light (BBL) treatments, so that diseased and abnormal vessels are destroyed ...

      Read Full Article
    18. Two thousand optometrists geared up for OCT at Specsavers

      Two thousand optometrists geared up for OCT at Specsavers

      More than 2000 optometrists at Specsavers have completed an extensive programme of Optical Coherence Tomography (OCT) training, ahead of the installation of the hospital-grade technology in their stores. The milestone has been reached almost half way through the rollout across the UK and Ireland of OCT, which is now in use in 400 stores. Richard Davies of the Bath store was the 2000 th optometrist to complete the set of seven online modules, which cover essentials of OCT, OCT in glaucoma, medical retina and anterior segment, and prudent referrals. Presenting a £100 voucher to Richard in store this week, Paul ...

      Read Full Article
    19. Carl Zeiss Meditec expands leadership position in treating glaucoma by investing in MicroOptx, Inc.

      Carl Zeiss Meditec expands leadership position in treating glaucoma by investing in MicroOptx, Inc.

      Today, Carl Zeiss Meditec announced that it has become a shareholder of MicroOptx Inc., headquartered in Minneapolis, MN. MicroOptx is a privately held company focused on innovative minimally invasive glaucoma surgery (MIGS) devices for surgical treatment of glaucoma. Their surgical technology is designed to provide effective reduction of intraocular pressure (IOP) with a simple surgical procedure. ZEISS supports breakthrough surgical treatments for glaucoma and believes MicroOptx’s MIGS solution will complement our leading portfolio of equipment and consumables in ophthalmic surgery. “The investment in MicroOptx will give ZEISS an early position in this new technology designed to increase MIGS adoption ...

      Read Full Article
    20. 3D Printer Powered by Machine Vision and Artificial Intelligence

      3D Printer Powered by Machine Vision and Artificial Intelligence

      Objects made with 3D printing can be lighter, stronger, and more complex than those produced through traditional manufacturing methods. But several technical challenges must be overcome before 3D printing transforms the production of most devices. ADVERTISEMENT Commercially available printers generally offer only high-speed, high-precision, or high-quality materials. Rarely do they offer all three, limiting their usefulness as a manufacturing tool. Today, 3D printing is used mainly for prototyping and low-volume production of specialized parts. Now Inkbit, a startup out of MIT, is working to bring all of the benefits of 3D printing to a slew of products that have never ...

      Read Full Article
      Mentions: Inkbit
    21. SID DisplayWeek a great success for Mirrorcle Technologies

      SID DisplayWeek a great success for Mirrorcle Technologies

      What a show it was! For the first time in company history, the Mirrorcle Technologies team exhibited at the Innovation Zone (or ‘I-Zone’) at the Society for Information Display (‘SID’) DisplayWeek 2019 exhibition in San Jose in early May, showcasing its new RGB Playzer products that are capable of full color projection by combining red, green and blue light sources. Visitors were able to interact with multiple MEMS-mirror based tabletop demos enhanced by additional laser projectors that “drew” colorful vector graphics content onto the carpeted walkways of the I-Zone. At virtually all times, a crowd of interested Silicon Valley movers ...

      Read Full Article
    22. Avinger Announces Successful Treatment of 1,000th Patient with Next-Generation Pantheris Device

      Avinger Announces Successful Treatment of 1,000th Patient with Next-Generation Pantheris Device

      Avinger, Inc. (AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that physicians in 78 clinical sites have successfully treated more than 1,000 patients with the next-generation Pantheris image-guided atherectomy system. The next-generation Pantheris was launched on a limited basis in the U.S. following receipt of 510(k) clearance by the U.S. Food and Drug Administration (FDA) in late May 2018 and features a number of improvements intended to augment the performance and reliability of the product. Importantly ...

      Read Full Article
      Mentions: FDA Avinger
    23. Ping An completes multi-center clinical trials for world's first intelligent OCT retinal disease screening system

      Ping An completes multi-center clinical trials for world's first intelligent OCT retinal disease screening system

      Ping An Insurance (Group) Company of China, Ltd. is pleased to announce that its technology arm, Ping An Technology, has completed a prospective multi-center clinical trial for the world's first intelligent optical coherence tomography (OCT) retinal disease screening system. The screening system is jointly developed by Ping An Technology and US-based Optovue, Inc. It is the first artificial intelligence (AI) imaging and screening system in the world that seamlessly integrates an OCT retinal imaging device and AI lesion detection software. The clinical trial was conducted at three well-known research institutions, the Eye and ENT Hospital of Fudan University in ...

      Read Full Article
    1-24 of 1170 1 2 3 4 ... 47 48 49 »
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. Popular Articles

  3. People in the News

    1. (1 articles) Kester Nahen
    2. (1 articles) Eman Namati
  4. OCT Companies in the News

    1. (2 articles) Avinger
    2. (1 articles) Notal Vision
    3. (1 articles) Perimeter Medical Imaging
    4. (1 articles) Altris AI
    5. (1 articles) Huvitz
    6. (1 articles) NinePoint Medical